- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06074510
FIR(양호 중간 위험도) 전립선암이 있는 남성의 PYLARIFY® PET/CT 또는 PET/MRI (MIRROR)
새로 진단된 호의적 중간 위험도(FIR) 전립선암이 있는 남성을 대상으로 한 PYLARIFY® PET/CT 또는 PET/MRI에 대한 제4상 공개 라벨 다기관 연구
The purpose of this study is to learn whether PYLARIFY PET imaging (study scan) can safely and accurately detect the presence or absence of prostate cancer growing beyond the prostate gland in men with favorable intermediate risk prostate cancer.
Participants will receive a single dose of PYLARIFY injection followed by a single whole-body PET/CT or PET/MRI scan acquired at 1 to 2 hours after PYLARIFY injection. Participants with positive study scan results that are suspicious for prostate cancer outside of the prostate gland may be asked to undergo additional diagnostic test(s) and/or recommend certain treatment(s) for prostate cancer within 2 to 90 days after the study scan. Participants will be monitored for up to 12 months to collecting information about treatment they receive for prostate cancer and results of regular PSA blood draws if ordered by doctors for up to 12 months after the study scan.
연구 개요
연구 유형
등록 (실제)
단계
- 4단계
연락처 및 위치
연구 장소
-
-
Alabama
-
Birmingham, Alabama, 미국, 35249
- University of Alabama at Birmingham
-
-
California
-
Irvine, California, 미국, 92618
- Hoag Cancer Center
-
Los Angeles, California, 미국, 90048
- Tower Urology
-
San Francisco, California, 미국, 94158
- University of California San Francisco
-
-
Georgia
-
Atlanta, Georgia, 미국, 30322
- Emory University
-
-
Iowa
-
Iowa City, Iowa, 미국, 52242
- University of Iowa Health Care
-
-
Maryland
-
Baltimore, Maryland, 미국, 21205
- Johns Hopkins University
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02114
- Massachusetts General Hospital
-
-
Michigan
-
Detroit, Michigan, 미국, 48201
- Karmanos Cancer Institute Wayne State University
-
Grand Rapids, Michigan, 미국, 49503
- BAMF Health
-
-
Missouri
-
St Louis, Missouri, 미국, 63110
- Washington University School of Medicine
-
-
Ohio
-
Cleveland, Ohio, 미국, 44195
- Cleveland Clinic
-
-
Oregon
-
Portland, Oregon, 미국, 97239
- Oregon Health & Science University
-
-
Utah
-
Salt Lake City, Utah, 미국, 84112
- Huntsman Cancer Institute University of Utah
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Patients must have the ability to understand and sign an approved informed consent form (ICF)
-
Patients must have the ability to understand and comply with all protocol requirements
-
Patients must be ≥ 18 years of age
-
Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
-
Patients with life expectancy of at least 13 months as determined by the investigator
-
Patients must have confirmed favorable intermediate risk (FIR) adenocarcinoma of the prostate per 2023 NCCN guidelines. FIR risk group confirmation includes all the following:
- 1 intermediate risk factor (cT2b-cT2c or ISUP Grade Group 2 or PSA 10-20 ng/mL)
- ISUP Grade Group 1 or 2
- <50% biopsy cores positive (e.g., <6 of 12 cores)
Note: Date of the prostate biopsy should be no sooner that 2 weeks and no later than 3 months prior to PYLARIFY PET imaging
Exclusion Criteria:
- Patients administered any high energy (>300 KeV) gamma-emitting radioisotope within 5 physical half-lives prior to Day 1 (PYLARIFY imaging)
- Previous Prostate cancer treatment including radiation, androgen deprivation therapy, brachytherapy, surgery, prostate ablation, hormonal therapies or investigational therapy
- Known hypersensitivity to the components of PYLARIFY or its analogs
- Patients with any medical condition or other circumstances that, in the opinion of the investigator, compromise the safety or compliance of the subject to produce reliable data or complete the study
- Patients who have any radiographic evidence of T3, N1 or M1 disease on SOC imaging (if performed)
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 특수 증상
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: 필라리파이 펫
|
Participants will receive a single dose of 333 MBq (9 mCi) [296 MBq-370 MBq (8 mCi - 10 mCi)] PYLARIFY injection followed by a single whole-body PET/CT or PET/MRI scan acquired at 1 to 2 hours post-dosing
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Detection rate
기간: Day 1
|
The proportion of participants with prostate cancer in whom PYLARIFY PET detected previously occult intraprostatic ISUP grade ≥3 lesions as assessed by pathology, or in whom PYLARIFY PET detected the presence of either/or extraprostatic extension, seminal vesicle invasion, regional lymph node involvement, distant metastases, divided by the number of subjects who undergo a PYLARIFY PET scan |
Day 1
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
이상반응이 발생한 참가자 수
기간: 1일차
|
1일차
|
|
|
Change in intended patient clinical management
기간: Day 30
|
Intended medical management plan before and after PYLARIFY PET imaging |
Day 30
|
|
True detection rate
기간: Day 1
|
The percentage of participants with at least one true positive lesion identified on PYLARIFY PET imaging and confirmed by the truth standard. This measure includes patients in whom PYLARIFY PET detected previously occult intraprostatic ISUP grade ≥3 lesions as confirmed by pathology; or patients in whom PYLARIFY PET detected the presence of either/or extraprostatic extension, seminal vesicle invasion, regional lymph node involvement, distant metastases as assessed by central readers and verified by the standard of truth. |
Day 1
|
|
Correct localization rate
기간: up to day 90
|
The percentage of participants for whom there is a one-to-one correspondence on the same side between the location of at least one lesion outside of prostate capsule (extraprostatic extension, seminal vesicle invasion, pelvic lymph nodes, extrapelvic lymph nodes, extrapelvic bone or extrapelvic soft tissue lesion(s) identified on PYLARIFY PET/CT or PET/MR and the standard of truth. |
up to day 90
|
|
Positive predictive value of PYLARIFY
기간: up to day 90
|
The percentage of participants who undergo PYLARIFY PET imaging that identifies a lesion or lesions outside of the prostate capsule and have an established standard of truth. Positive predictive value does not require a one-to-one correspondence by lesion location but requires that the lesion and standard of truth be within the same anatomic region, including prostatic, pelvic, extra-pelvic or distant lesions. |
up to day 90
|
|
Sensitivity of PYLARIFY
기간: up to day 90
|
Sensitivity at the patient level for patients who undergo prostate surgery for prostate and with pelvic lymph nodes removal. |
up to day 90
|
|
Specificity of PYLARIFY
기간: up to day 90
|
Specificity at the patient level for patients who undergo prostate surgery for prostate and with pelvic lymph nodes removal. |
up to day 90
|
|
Negative predictive value of PYLARIFY
기간: up to day 90
|
Negative predictive value at the patient level for patients who undergo prostate surgery for prostate and with pelvic lymph nodes removal. |
up to day 90
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- PYL4301
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .